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ChinaA B S T R A C TObjectives: To assess the health-related quality of life (HRQOL) and
willingness to pay (WTP) per quality-adjusted life-year (QALY) amount
of patients with epilepsy in China.Methods: Adults with epilepsy and
a healthy control were recruited in two tertiary hospitals in China.
Participants completed two indirect utility elicitation instruments
(Quality of Well-being Scale-self administered version and EuroQol
ﬁve-dimensional questionnaire) and a WTP questionnaire. Correla-
tions between sociodemographic or epilepsy-speciﬁc variables (age of
epilepsy onset, duration of epilepsy, seizure types, types of antiepi-
leptic drug treatment, etc.) and HRQOL or WTP/QALY were assessed to
identify the candidate predictor. Multiple linear regression models
were adopted to investigate the predictive performances of identiﬁed
candidate predictors. Data analyses were performed on SPSS 20.0
(SPSS, Inc., Chicago, IL). Results: For utilities of both the Quality of
Well-being Scale-self administered version and the EuroQol ﬁve-
dimensional questionnaire, patients with epilepsy had statistically
lower values than did the control group (P o 0.0001). In terms of the
WTP/month, the percentage of WTP accounting for the monthlyee front matter Copyright & 2015, International S
r Inc.
.1016/j.vhri.2015.03.019
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ndence to: Shu-Chuen Li, MS 108, Medical Sciencesincome and the WTP/QALY values from the epilepsy group were
substantially higher than those from the control group (P o 0.0001).
WTP=QALY¼ 12
WTP
Month
1Utility ðCurrent HealthÞ
The multiple linear regression model identiﬁed working status
(P ¼ 0.05), seizure types (P ¼ 0.022), income (P ¼ 0.006), and self-rating
health state (Po 0.05) as predictors of HRQOL while income (P ¼ 0.000)
and self-rating health state (P o 0.05) statistically contributed to the
variations in WTP/QALY value for the epilepsy group. Conclusions:
Patients with epilepsy had substantially lower HRQOL than did the
healthy population.
Keywords: China, cost-effectiveness analysis, epilepsy, health-related
quality of life, willingness to pay.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Epilepsy, as a chronic disorder, has considerable negative impact
on people’s day-to-day functioning [1], including impact on
cognitive function, self-esteem, and excessive psychological bur-
den (e.g., depression and anxiety) [2–4]. Meanwhile, epilepsy is
also well recognized to pose a heavy economic burden on the
society and the individual, as indicated in many cost-of-illness
studies [5–10]. Although the health-related quality of life (HRQOL)
of patients with epilepsy, however, has been investigated in a
series of studies, most of these studies were performed in
developed countries. Within the developing countries, the rela-
tively few studies that unanimously adopted epilepsy-speciﬁc or
generic non–preference-based instruments (e.g., Quality of Life inEpilepsy Inventory-89 (QOLIE-89, QOLIE-31, short-form 36 health
survey, and WHO Quality of Life-BREF (WHOQOL-BREF) to assess
the HRQOL [11–15], from those measures, consequently, cannot
be integrated into cost-effectiveness analysis.
In contrast, the Quality of Well-being Scale-self-administered
version (QWB-SA) and the EuroQol ﬁve-dimensional question-
naire (EQ-5D) are generic preference-based instruments that
could estimate the quality-adjusted life-years (QALYs). QALY
provides a common currency to assess the extent of beneﬁts
gained from various interventions, thus allowing comparison of
the effectiveness of health technologies for different diseases.
Furthermore, to make any health resource allocation nowadays,
it is necessary to go beyond assessing just the effectiveness of the
new drug or the health technology and perform a cost-effectivenessociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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estimates the incremental cost-effectiveness ratio (ICER) by compar-
isons between two interventions. Common decision rules indicate
that an intervention is “good value for money” if the ICER falls below
a certain cost-effectiveness threshold. The chosen threshold reﬂects
the acceptable value of a health gain within a speciﬁc decision-
making context. In practice, many economic evaluations adopted 1
to 3 times of the speciﬁc country’s gross domestic product per capita
as the willingness-to-pay (WTP) per QALY threshold according to the
recommendation by the World Health Organization (WHO) [16].
Another popular approach used to deﬁne the cost-
effectiveness threshold is through the use of contingent valu-
ation. Despite its popularity, there are issues with the obtained
WTP estimates. First, the estimates obtained can vary substan-
tially by the elicitation method used (e.g., ex post and ex ante
perspectives can create different WTP values). Second, it is
important that the WTP estimates obtained are relevant to the
decision-making context. Nevertheless, in spite of these issues,
WTP studies could provide valuable information to policymakers
on the magnitude of individuals’ preferences and may better
reﬂect societal value [17].
Moreover, rather than using decision rules such as league
tables or the ICER threshold value recommended by the WHO, it
may be more reasonable to allocate health care resources on the
basis of the societal WTP for health care beneﬁts [18]. This is
particularly important for developing countries, including China,
because the threshold value recommended by the WHO may be
overestimating the WTP values. So, we believe that it might
overestimate the true WTP value in China. Adopting these recom-
mendations would therefore likely lead to inappropriate decision
making. Hence, investigations on the societal WTP threshold for
health care beneﬁts should be a “research priority” [19].
Unfortunately, there is a paucity of this type of studies,
particularly in developing countries. Nevertheless, a WTP/QALY
threshold study was conducted recently in China by Zhao et al.
[20] on patients with chronic prostatitis by measuring the utility
(measured by the EQ-5D and the six-dimensional health state
short form [derived from SF-36]) and the WTP simultaneously. In
that study, based on the indirect preference elicitation method
(using the EQ-5D and the six-dimensional health state short form
[derived from SF-36]), the WTP/QALY value was successfully
elicited for both chronic prostatitis and general populations, with
a higher WTP/QALY value in the chronic prostatitis group. In
addition, the reported values were close to the lower bound of the
WHO-recommended WTP/QALY threshold, but the authors sug-
gested that the type of disease may have an impact on the
threshold value.
When it comes to the management of epilepsy, in view of
extreme limited access to advanced antiepileptic treatments, due
to constraints in health care resources, patients with epilepsy in
China (and in this case also other developing countries) might
experience more problems than do their Western counterparts.
There is a strong rationale for assessing their HRQOL to evaluate
the impact of their antiepileptic treatment.
At the same time, we attempted to value the QALY by using
the WTP approach in patients with epilepsy and compare their
HRQOL and WTP/QALY values with those of the general popula-
tion. To our knowledge, the empirical WTP/QALY threshold
estimations are available only in two Asian countries (one was
for the general population only and the other was for both chronic
prostatitis and general populations) [20,21] and there is only one
study that investigated the WTP value for patients with epilepsy
from Norway [22]. Because the WTP/QALY threshold plays a
signiﬁcant role in health care resource allocation, our study would
contribute to the resolution of some of the controversies in the
determination of an ICER threshold value, especially in countries/
regions with less developed economic status.Methods
Subjects
The cross-sectional study recruited participants between July and
October 2012 from two tertiary hospitals in China with speciﬁc
Institutional Ethics Review Board approval: Renmin Hospital of
Wuhan University and the Fifth Hospital of Wuhan (Wuhan,
Hubei, China). After informed consent was received from each
adult participant, a convenient sample of inpatients or out-
patients with diagnosis of epilepsy and a control group (without
manifestation of cognitive problems) were recruited. Healthy
controls were primarily from the relatives of the patients with
epilepsy, medical students, interns, and hospital general staff
and were blind to the study design. We do not think that it will
bias the result. Each subject was interviewed by a trained
interviewer using standardized questionnaires containing the
QWB-SA, the EQ-5D/visual analogue scale (VAS), and the WTP
questionnaire.
Instruments
QWB-SA
The QWB-SA assesses the presence/absence of symptoms or
problems, persons’ mobility, physical activity, and social activity.
Each participant recalls the answers to particular QWB-SA ques-
tion within the last 3 days. The preference weights were derived
from a community sample [23]. The scoring algorithm and
preference weights were provided by the University of California,
San Diego Health Services Research Center. The use of the QWB-
SA in our study was authorized by the QWB-SA copyright owner,
and the validity of Chinese-language QWB-SA was reported by
our study group previously [24].
EQ-5D/VAS
The EQ-5D comprises ﬁve dimensions: mobility, self-care, usual
activity, pain/discomfort, and anxiety/depression. The utility scor-
ing algorithm adopted in our study was developed using time
trade-off (TTO)-based preference scores [25] from a UK general
population [26]. The EQ-VAS is a 20-cm vertical VAS ranging from
100 (best imaginable health state) to 0 (worst imaginable health
state) to represent the overall health of the day.
The WTP questionnaire
The contingent valuation method was adopted to elicit the WTP
value. A respondent would be provided with an initial bid and
asked whether he or she would like to pay this amount of money
on a monthly basis to move from his or her current health state
to a perfect health state. If subjects answered positively (neg-
atively), the amount was increased (decreased) by the speciﬁed
amount. The maximum bidding amount offered would be
dependent on respondent’s monthly income (maximum price
permitted for the close-ended iterative bidding was 10 times the
subject’s own monthly income) [18]. If the respondent was willing
to pay less than the minimum offered bid or higher than the
maximum offered bid, his or her WTP amount was determined
using open-ended questions. Besides, each respondent would be
reminded that the payment cannot be covered by the health care
insurance and would reduce the amount of money that could be
used in other ways before he or she responds to the bidding game
question. To minimize the starting bid bias, ﬁve initial bids of US
$139, US $224, US $300, US $399, and US $689, representing low,
low to middle, middle, middle to high, and high average monthly
income in China, were randomly assigned to respondents
(National Bureau of Statistics of China, 2012, exchange rate US
V A L U E I N H E A L T H R E G I O N A L I S S U E S 6 C ( 2 0 1 5 ) 8 9 – 9 7 91$1 ¼ 6.2353 CNY, December 2012) (see Appendix-WTP question-
naire in Supplemental Materials found at http://dx.doi.org/10.
1016/j.vhri.2015.03.019) [27].
Data Analyses
HRQOL
Continuous variables were presented by mean, SD/standard
error, median, interquartile range, and range where applicable,
whereas categorical variables were presented by the number and
proportion of the entire sample in the corresponding group.
Differences between epilepsy and control groups were assessed
by using independent-sample analysis of variance (if the distribu-
tion was normal) or the Manny-Whitney U test (if the distribution
was skewed) n case of continuous variables and the chi-square
test in case of categorical variables. Correlations between socio-
demographic or epilepsy-speciﬁc variables and HRQOL utility
scores were assessed via Spearman’s correlation coefﬁcient with
P-value less than 0.1 to identify candidate predictors.
Multiple linear regression (MLR) analysis was performed to
investigate the associations between sociodemographic or
epilepsy-speciﬁc variables (that were signiﬁcantly correlated with
HRQOL as identiﬁed by Spearman’s correlation tests) and HRQOL
utility scores.
WTP/QALY
Analyses were based on subjects who fully completed the ques-
tionnaire. Continuous variables were compared using the Mann-
Whitney U test, and chi-square tests were used to compare the
categorical variables. The WTP/QALY ratio for each participant
was computed through the following formula:
WTP=QALY¼ 12
WTP
Month
1Utility ðCurrent HealthÞ
Because only 1-year payment was captured, life expectancy and
discount rate were not considered. Because of the arithmetic
attribute (denominator is zero) of the formula, subjects with
perfect health states (deﬁned as utility of 1) were excluded from
the WTP/QALY computation regardless of the groups they
belonged to. Differences in WTP/QALY values between epilepsy
and control groups were compared by using the Mann-Whitney
U test.
Correlations between sociodemographic or epilepsy-speciﬁc
variables and WTP/QALY value were assessed via Spearman’s
correlation coefﬁcient with P-value less than 0.1 to identify
candidate predictors. In addition, MLR analysis was undertaken
to assess associations between sociodemographic or epilepsy-
speciﬁc variables (that were signiﬁcantly correlated with the
WTP/QALY value according to the Spearman’s correlation coef-
ﬁcients) and the WTP/QALY value. To allow for better interpre-
tation, the monthly income was grouped into four categories, US
$224 or less (low), US $225 to 300 (lower-middle), US $301 to 689
(upper-middle), and US $ 700 or more (high) [27].
The following variables were considered potential factors:
sociodemographic: sex, marital status, age, and working status;
epilepsy-speciﬁc: age of epilepsy onset, duration of epilepsy,
seizure types (partial seizures and generalized seizures), seizure
frequency, current antiepileptic drugs (monotherapy vs. poly-
therapy), refractory epilepsy, epileptic discharges (electroence-
phalogram), positive lesions on brain computed tomography/
magnetic resonance imaging, brain trauma/disease, and brain
surgery history. All signiﬁcant categorical variables (e.g., marital
status and diagnosis) were grouped by dummy variables if they
were selected in the MLR analysis.
All data analyses were performed using SPSS 20.0 (SPSS, Inc.,
Chicago, IL).Results
Participants
Overall, 144 patients with epilepsy and 312 healthy controls
completed the QWB-SA and the EQ-5D. Among these, 41 partic-
ipants in the control group failed to complete the WTP ques-
tionnaire, 25 subjects in the control group reported perfect health
state on the QWB-SA, and 59 patients with epilepsy and 164
controls reported full utility on the EQ-5D; thus, they were
excluded from corresponding analyses.
Demographic Variables
There were statistically signiﬁcant differences between epilepsy
and control groups in terms of age (P ¼ 0.033), sex (P o 0.0001),
working status (P ¼ 0.029) (employed vs. unemployed), education
(P o 0.0001), and monthly income (P o 0.0001) (Table 1).
Description Statistics of the QWB-SA and the EQ-5D
Utility scores for both the QWB-SA and the EQ-5D were signiﬁ-
cantly different between epilepsy and healthy control groups (Po
0.0001), whereas the EQ-VAS did not show a difference between
the two groups (P ¼ 0.052). Two of the four sections of the QWB-
SA, namely, CPX (P o 0.0001) and SAC (P o 0.0001), were
signiﬁcantly different between epilepsy and control groups, with
patients with epilepsy tending to experience more problems in
these two sections (Table 1).
Description Statistics of WTP/Month, and WTP/QALY
Among subjects with completed WTP questionnaire, patients
with epilepsy reported lower utility scores on both the QWB-SA
and the EQ-5D than did the control group (Po 0.0001). In terms of
the WTP/month and WTP as percentage of the monthly income,
values from the epilepsy group were substantially higher than
those from the control group (both with Po 0.0001). Likewise, the
WTP/QALY value showed the same trend. The epilepsy group
provided a WTP/QALYQWB-SA value (median [interquartile range])
of US $ 8799 (10,570), whereas the control group generated a value
of US $1740 (4524) (P o 0.0001). In addition, when the EQ-5D was
adopted as the utility measure, the same tendency was shown
accompanied by an even higher WTP/QALYEQ-5D value in the two
groups (US $ 9446 [12, 843] vs. 2917 [5700]; P o 0.0001) (Table 2).
The starting bid might introduce a bias to the ﬁnal result, and
to address this, the Kruskal-Wallis H test was undertaken to
assess differences in the WTP value for the ﬁve starting bids. The
results indicated that there was no signiﬁcant inﬂuence on the
ﬁnal WTP value from the different initial bids.
Relationships between Sociodemographic or Epilepsy-Speciﬁc
Variables and HRQOL
For the epilepsy group, age (0.260, P ¼ 0.002), marital status
(0.188, P ¼ 0.024), working status (0.213, P ¼ 0.010), seizure types
(0.138, P ¼ 0.098), age of epilepsy onset (0.190, P ¼ 0.023),
refractory epilepsy (0.220, P ¼ 0.008), seizure frequency (0.178,
P ¼ 0.033), monthly income (0.296, P o 0.001), QWB-SA self-
rating health state (0.525, Po 0.001), and the EQ-VAS (0.475, Po
0.001) were found to be positively or negatively correlated with
utility scores of the QWB-SA according to Spearman’s correlation
coefﬁcients, whereas age (0.254, P ¼ 0.002), marital status (0.174,
P ¼ 0.037), working status (0.282, P ¼ 0.001), seizure types (0.165,
P ¼ 0.048), age of epilepsy onset (0.175, P ¼ 0.036), brain trauma/
disease (0.137, P ¼ 0.101), brain surgery history (0.152, P ¼
0.070), QWB-SA self-rating health state (0.441, P o 0.001), and
Table 1 – Characteristics and HRQOL results of patients with epilepsy and the control population.
Characteristic Epilepsy
(n ¼ 144)
Simple partial
(n ¼ 7)
Complex partial
(n ¼ 83)
Secondary generalized
(n ¼ 50)
Tonic-clonic generalized
(n ¼ 4)
Control
(n ¼ 312)
Age (y), mean  SD 33.11  13.044 27.43  12.040 33.95  12.930 31.66  12.847 43.75  16.540 34.52  15.662
16–29 68 (47.2) 5 (71.4) 36 (43.4) 26 (52.0) 1 (25) 144 (46.2)
30–39 31 (21.5) 0 20 (24.1) 10 (20.0) 1 (25) 36 (11.5)
40–49 28 (19.4) 2 (28.6) 16 (19.3) 10 (20.0) 0 (0) 54 (17.3)
50–59 11 (7.6) 0 9 (10.8) 1 (2.0) 1 (25) 47 (15.1)
Z60 6 (4.2) 0 2 (2.4) 3 (6.0) 1 (25) 31 (9.9)
Sex: male (%) 52.1 0 57.8 48.0 75.0 38.8
Han ethnicity 142 (98.6) 7 (100.0) 82 (98.8) 49 (98.0) 4 (100.0) 308 (98.7)
Education (y), mean  SD 10.56  2.961 10.00  3.162 10.41  2.745 11.02  3.298 9.00  2.449 13.16  2.871
r6 16 (11.1) 1 (14.3) 7 (8.4) 7 (14.0) 1 (25.0) 16 (5.1)
7–12 106 (73.6) 5 (71.4) 66 (79.5) 32 (64.0) 3 (75.0) 139 (44.6)
412 22 (15.3) 1 (14.3) 10 (12.0) 11 (22.0) 0 157 (50.3)
Marital status
Unmarried 71 (49.3) 4 (57.1) 42 (50.6) 24 (48.0) 1 (25.0) 123 (39.4)
Married 70 (48.6) 2 (28.6) 40 (48.2) 25 (50.0) 3 (75.0) 184 (59.0)
Divorced 2 (1.4) 1 (14.3) 1 (1.2) 0 0 2 (0.6)
Widow/widower 1 (0.7) 0 0 1 (2.0) 0 3 (1.0)
Working status
Employed 65 (45.1) 4 (57.1) 37 (44.6) 22 (44.0) 2 (50.0) 175 (56.1)
Unemployed 69 (54.9) 3 (42.9) 46 (55.4) 28 (56.0) 2 (50.0) 137 (43.9)
Age of onset (y), mean  SD 23.22  14.726 19.43  11.688 24.90  14.396 20.12  14.553 33.50  22.927 –
Duration (y), mean  SD 9.64  9.142 8.86  11.393 8.80  7.852 11.11  10.710 10.25  10.404 –
Brain trauma/disease (%) 31.94 (n ¼ 46) 42.86 (n ¼ 3) 30.12 (n ¼ 25) 32.00 (n ¼ 16) 50.00 (n ¼ 2) –
Brain surgery (%) 15.28 (n ¼ 22) 14.29 (n ¼ 1) 16.87 (n ¼ 14) 12.00 (n ¼ 6) 25.00 (n ¼ 1) –
Head CT/MRI (%) 30.56 (n ¼ 44) 14.29 (n ¼ 1) 33.73 (n ¼ 28) 26.00 (n ¼ 13) 50.00 (n ¼ 2) –
EEG (%) 43.06 (n ¼ 62) 71.43 (n ¼ 5) 39.76 (n ¼ 33) 42.00 (n ¼ 21) 75.00 (n ¼ 3) –
Refractory epilepsy (%) 25.69 (n ¼ 37) 14.29 (n ¼ 1) 25.30 (n ¼ 21) 28.00 (n ¼ 14) 25.00 (n ¼ 1) –
Seizure frequency (%)
Daily 3.47 (n ¼ 5) 0 (n ¼ 0) 3.61 (n ¼ 3) 4.00 (n ¼ 2) 0 (n ¼ 0) –
Weekly 11.81 (n ¼ 17) 0 (n ¼ 0) 8.43 (n ¼ 7) 20.00 (n ¼ 10) 0 (n ¼ 0) –
Monthly 29.17 (n ¼ 42) 42.86 (n ¼ 3) 22.89 (n ¼ 19) 36.00 (n ¼ 18) 50.00 (n ¼ 2) –
Bimonthly 10.42 (n ¼ 15) 0 (n ¼ 0) 9.64 (n ¼ 8) 12.00 (n ¼ 6) 25.00 (n ¼ 1) –
Quarterly 21.53 (n ¼ 31) 0 (n ¼ 0) 31.33 (n ¼ 26) 10.00 (n ¼ 5) 0 (n ¼ 0) –
Half-yearly 9.03 (n ¼ 13) 28.57 (n ¼ 2) 10.84 (n ¼ 9) 4.00 (n ¼ 4) 0 (n ¼ 0) –
Yearly 10.42 (n ¼ 15) 28.57 (n ¼ 2) 10.84 (n ¼ 9) 6.00 (n ¼ 3) 25.00 (n ¼ 1) –
More than yearly 4.17 (n ¼ 6) 0 (n ¼ 0) 2.41 (n ¼ 2) 8.00 (n ¼ 4) 0 (n ¼ 0) –
QWB-SA
Mean  SD 0.657  0.135 0.681  0.146 0.636  0.135 0.687  0.127 0.671  0.174 0.802  0.155
Median  IQR 0.673  0.172 0.744  0.216 0.673  0.134 0.676  0.133 0.707  0.321 1.000  0.152
continued on next page
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QWB-SA self-rating health status
Excellent 2 (1.4) 0 1 (1.2) 1 (2.0) 0 37 (11.5)
Very good 26 (18.1) 0 14 (16.9) 12 (24.0) 0 86 (26.6)
Good 53 (36.8) 5 (71.4) 28 (33.7) 17 (34.0) 3 (75.0) 94 (29.1)
Fair 56 (38.9) 2 (28.6) 36 (43.4) 17 (34.0) 1 (25.0) 98 (30.3)
Poor 7 (4.9) 0 4 (4.8) 3 (6.0) 0 8 (2.5)
EQ-5D
Mean  SD 0.828  0.206 0.890  0.148 0.798  0.211 0.867  0.203 0.854  0.170 0.923  0.132
Median  IQR 0.848  0.275 1.000  0.275 0.848  0.275 1.000  0.204 0.863  0.302 1.000  0.152
EQ-VAS
Mean  SD 79.57  16.419 74.43  20.239 79.63  16.835 79.80  15.935 84.50  6.403 82.64  13.939
Median  IQR 80.00  20.00 69.00  38.00 80.00  20.00 80.00  20.00 85.00  11.50 85.00  11.00
Income
r1500 (US $241) 9 (6.3) 0 4 (4.8) 4 (8.0) 1 (25.0) 0
1501–2000 (US $241–321) 25 (17.4) 2 (28.6) 17 (20.5) 5 (10.0) 1 (25.0) 4 (1.6)
2001–3000 (US $321–482) 43 (29.9) 1 (14.3) 24 (28.9) 17 (34.0) 1 (25.0) 83 (33.7)
3001–4000 (US $482–643) 44 (30.6) 3 (42.9) 24 (28.9) 16 (32.0) 1 (25.0) 113 (45.9)
4001–5000 (US $643–803) 12 (8.3) 1 (14.3) 8 (9.6) 3 (6.0) 0 43 (17.5)
Z5000 (US $803) 11 (7.6) 0 6 (7.2) 5 (10.0) 0 3 (1.2)
CT, computed tomography; EEG, electroencephalogram; EQ-5D, EuroQol ﬁve-dimensional questionnaire; HRQOL, health-related quality of life; IQR, interquartile range; MRI, magnetic resonance
imaging; QWB-SA, Quality of Well-being Scale-self administered version; VAS, visual analogue scale.
Table 2 – Utilities, WTP/mo, and WTP/QALY values (Median [IQR]).
Variable Utility and WTP N WTP/QALY
Epilepsy Control P-value Epilepsy N Control P-value
Total N ¼ 144 N ¼ 271
QWB-SA 0.673 (0.172) 0.775 (0.258) o0.0001 144 8,799.265(10,570.02) 246 1740.388(4523.505) o0.0001
EQ-5D 0.848 (0.275) 1.000 (0.152) o0.0001 85 9,446.073(12,843.369) 107 2916.54(5700.217) o0.0001
WTP/mo 241.014 (184.777) 48.203 (160.676) o0.0001 / / / / /
Percentage 0.465 (0.267) 0.100 (0.267) o0.0001 / / / / /
Note. Money was presented as US $; US $1 ¼ 6.2237 CNY (January 2013). Percentage calculated via WTP/mo divided by monthly income.
EQ-5D, EuroQol ﬁve-dimensional questionnaire; IQR, interquartile range; QALY, quality-adjusted life-years; QWB-SA, Quality of Well-being Scale-self administered version; WTP, willingness
to pay.
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utility scores of the EQ-5D (see Appendix Table 1 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.vhri.2015.03.019).
For the control group, utility scores of both the QWB-SA and
the EQ-5D were signiﬁcantly correlated with age, marital status,
education, QWB-SA self-rating health state, and the EQ-VAS.
Monthly income, however, was not shown to be associated with
HRQOL of the healthy population (see Appendix Table 2 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.vhri.
2015.03.019).
Relationships between Sociodemographic Variables or
Epilepsy-Speciﬁc Variables and WTP/QALY
For QWB-SA utility score–based WTP/QALY calculations by epi-
lepsy group, working status (0.141, P ¼ 0.091), duration of epilepsy
(0.149, P ¼ 0.074), refractory epilepsy (0.242, P ¼ 0.003), QWB-
SA self-rating health state (0.332, P ¼ 0.000), the EQ-VAS (0.235,
P ¼ 0.005), and monthly income (0.752, P ¼ 0.000) were signiﬁ-
cantly associated with WTP/QALYQWB-SA values. When the WTP/
QALY value was derived from the EQ-5D utility score, it was
statistically correlated only with working status (0.220, P ¼ 0.043),
QWB-SA self-rating health state (0.333, P ¼ 0.002), and monthly
income (0.296, P ¼ 0.000) (see Appendix Table 3 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.vhri.2015.03.019).Table 3 – Multiple linear regression analyses for HRQOL
QWB-SA
Model 1
enter
R2 Standardized
coefﬁcient β
Signiﬁcance
0.226
Age 0.149 0.290
Marital status 0.102 0.289
Working status 0.143 0.078
Diagnosis 0.179 0.022
Age of onset 0.092 0.462
Seizure frequency 0.165 0.172
Refractory
epilepsy
0.060 0.535
Income 0.217 0.006
Model 2
enter
R2 Standardized
coefﬁcient β
Signiﬁcance
0.421
Age 0.068 0.584
Marital status 0.151 0.076
Working status 0.095 0.196
Diagnosis 0.121 0.078
Age of onset 0.031 0.283
Refractory 0.018 0.833
Seizure frequency 0.110 0.212
QWB-SA health
state
0.296 0.000
EQ-VAS 0.279 0.000
Income 0.172 0.013
EQ-5D, EuroQol ﬁve-dimensional questionnaire; HRQOL, health-related q
version; VAS, visual analogue scale. Bold terms and values are statisticaSpearman’s correlation coefﬁcients between sociodemo-
graphic variables and WTP/QALY for the control group are
presented in Appendix Table 4 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.vhri.2015.03.019.MLR Analyses for HRQOL
Epilepsy group
Two models were used to investigate the relationships between
sociodemographic or epilepsy-speciﬁc variables and utility scores
of the two instruments, with statistically signiﬁcant factors
(identiﬁed by Spearman’s correlation) as independent variables.
In the ﬁrst model, 22.6% of the variation in utility scores of the
QWB-SA was accounted for by the model while only seizure types
(standardized coefﬁcient β ¼ 0.179; P ¼ 0.022) and monthly
income (β ¼ 0.217; P ¼ 0.006) statistically contributed to the
model. In terms of model 2, the QWB-SA health state (β ¼ 0.296;
P ¼ 0.000), the EQ-VAS (β ¼ 0.279; P ¼ 0.000), and monthly income
(β ¼ 0.172; P ¼ 0.013) signiﬁcantly contributed to the model, with
42.1% of the variation in utility scores being accounted for by the
model. For utility scores derived from the EQ-5D, the two models
accounted for 14.9% and 37.0% of the variations in utilities,
respectively. Particularly, working status (β ¼ 0.166; P ¼ 0.050) in
model 1 and the QWB-SA health state (β ¼ 0.251; P ¼ 0.002) andscores of patients with epilepsy.
EQ-5D
Model 1
enter
R2 Standardized
coefﬁcient β
Signiﬁcance
0.149
Age 0.197 0.179
Marital status 0.056 0.579
Working status 0.166 0.050
Diagnosis 0.109 0.173
Age of onset 0.058 0.653
Brain injury/
disease
0.045 0.661
Brain surgery
history
0.176 0.091
Income 0.144 0.077
Model 2
enter
R2 Standardized
coefﬁcient β
Signiﬁcance
0.370
Age 0.081 0.534
Marital status 0.009 0.920
Working status 0.091 0.235
Diagnosis 0.064 0.361
Age of onset 0.059 0.600
Brain injury/
disease
0.065 0.471
Brain surgery
history
0.118 0.195
QWB-SA health
state
0.251 0.002
EQ-VAS 0.345 0.000
Income 0.085 0.235
uality of life; QWB-SA, Quality of Well-being Scale-self administered
lly signiﬁcant.
Table 4 – Multiple linear regression analyses for WTP/QALY of patients with epilepsy.
QWB-SA EQ-5D
Model 2 enter R2 Standardized
coefﬁcient β
Signiﬁcance Model enter R2 Standardized
coefﬁcient β
Signiﬁcance
0.510 0.497
Working status 0.051 0.415 Working status 0.103 0.209
Duration 0.121 0.055 QWB-SA health
state
0.248 0.003
Refractory
epilepsy
0.036 0.573 Monthly income 0.629 0.000
QWB-SA health
state
0.134 0.049 / / /
EQ-VAS 0.156 0.022 / / /
Monthly income 0.640 0.000 / / /
EQ-5D, EuroQol ﬁve-dimensional questionnaire; QALY, quality-adjusted life-year; QWB-SA, Quality of Well-being Scale-self administered
version; VAS, visual analogue scale; WTP, willingness to pay. Bold terms and values are statistically signiﬁcant.
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positively contribute to the variation (Table 3).
Control group
Both age (β ¼ 0.226, P ¼ 0.002, and β ¼ 0.173, P ¼ 0.014) and the
EQ-VAS (β ¼ 0.240, P ¼ 0.000, and β ¼ 0.356, P ¼ 0.000) statistically
contributed to the model in predicting utility scores for the QWB-
SA or the EQ-5D. In addition, QWB-SA utility scores could be
predicted by the QWB-SA health state (β ¼ 0.142; P ¼ 0.027) (see
Appendix Table 5 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.vhri.2015.03.019).
MLR Analyses for WTP/QALY
Epilepsy group
For either WTP/QALYQWB-SA or WTP/QALYEQ-5D, the QWB-SA
health state (β ¼ 0.134, P ¼ 0.049, and β ¼ 0.248, P ¼ 0.003)
and monthly income (β ¼ 0.640, P o 0.001, and β ¼ 0.629, P o
0.001) could be regarded as predictors of the WTP/QALY value,
with around 50% of the variation in the WTP/QALY value
predicted in the two models. Besides, the EQ-VAS contributed
to the variations in the values of WTP/QALYQWB-SA (β ¼ 0.640; Po
0.001) (Table 4).
Control group
Because the residual distribution of WTP/QALYQWB-SA values in
the control group was skewed, logarithm transformation wasTable 5 – Multiple linear regression analyses for WTP/QA
QWB-SA*
Enter R2 Standardized
coefﬁcient β
Signiﬁcance
0.099
Age 0.175 0.009
Monthly income 0.128 0.723
QWB-SA health
state
0.199 0.012
EQ-VAS 0.007 0.930
EQ-5D, EuroQol ﬁve-dimensional questionnaire; QALY, quality-adjusted
version; VAS, visual analogue scale; WTP, willingness to pay. Bold terms
* Log-transformed WTP/QALY was applied.applied to this value. Neither the WTP/QALYQWB-SA value nor the
WTP/QALYEQ-5D value, however, was satisfactorily predicted by
the models (R2 ¼ 0.099 and 0.104, respectively). When the WTP/
QALY value was calculated on the basis of the QWB-SA utility,
age (β ¼ 0.175; P ¼ 0.009) and the QWB-SA health state (β ¼ 0.199;
P ¼ 0.012) were predictors of the WTP/QALYQWB-SA value, whereas
the WTP/QALYEQ-5D value was predicted only by monthly income
(β ¼ 0.239; P ¼ 0.018) (Table 5).Discussion
The burden of epilepsy on a sufferer not only encompasses the
unpredictability of seizures but also includes the social exclusion
as a result of negative attitudes toward patients with epilepsy. For
instance, the stigma may even preclude adult patients from
marrying or being denied employment opportunities. Hence,
primary treatment goals should not just be to reduce the seizure
frequency and seizure severity but also to promote the quality of
life of those being affected. As such, factors that impact the
quality of life could become potential targets of antiepileptic
management. Furthermore, WTP/QALY, which theoretically
incorporates the cost of pain, suffering, anxiety, or fatigue because
of a disease, would measure the intangible. Hence, quantifying
WTP/QALY and the associated factors for patients with epilepsy
would provide a more accurate picture of the global burden of this
disease. To our knowledge, there was only one study that adopted
the WTP method to measure how much patients with epilepsyLY of the control population.
EQ-5D
Enter R2 Standardized
coefﬁcient β
Signiﬁcance
0.104
Age 0.098 0.441
Marital status 0.066 0.572
QWB-SA health
state
0.170 0.091
Monthly income 0.239 0.018
life-year; QWB-SA, Quality of Well-being Scale-self administered
and values are statistically signiﬁcant.
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that would cure epilepsy permanently [22]. Although the high
response rate indicated great acceptability, the associations
between WTP and other preference measures were low (Spear-
man’s correlation coefﬁcients ranged from 0.09 to 0.12 for WTP
and standard gamble [SG] or TTO). In addition, only 59 subjects
completed the study without a control group [22]. Nevertheless,
the median WTP amount was US $20,000 (which could inﬂate to
US $30,984 in 2012), accounting for 47% of the annual household
income in this aforementioned study. In terms of the proportion
of WTP-constituted income, our result (46.5%) was comparable to
this one.
With cost-effectiveness/cost-utility analysis increasingly
being adopted by various jurisdictions, quantifying the threshold
of cost-effectiveness analysis would offer a benchmark for
interpreting economic evaluation. Using the stated preference
data to quantify the WTP/QALY has been explored previously by
our study group, and this elicitation method for WTP/QALY ratio
was found to be acceptable and feasible, as well as produce
meaningful answers among Chinese subjects [20].
From our study, two interesting ﬁndings are worth noting:
ﬁrst, more predictors were identiﬁed for WTP/QALYQWB-SA than
for WTP/QALYEQ-5D, which might indicate better sensitivity of the
QWB-SA as a utility elicitation instrument. In addition, age was
capable of predicting WTP/QALYQWB-SA values for the healthy
population only, with more advanced age associated with greater
WTP per QALY value. Because the negative association between
HRQoLQWB-SA and age was shown in the normative data for the
QWB-SA (QWB-SA User Manual) as well as in our data set, it
might mean that the proportional increase in the WTP of the
healthy respondents with increasing age would exceed the
magnitude of the decrease in the utility as measured by the
QWB-SA. This was supported by the WTP/QALY value increasing
with increasing age in our study. In other words, this ﬁnding
suggested that the WTP value disproportionally increases with
age. Nonetheless, this ﬁnding was not consistent because one
study based on a community sample observed that there was a
negative association between age and WTP/QALY [28]. Another
review study, however, reported that relative to the baseline
assumption of 40 years, the WTP/QALY value would decrease by
7% for those aged 35 years and increase by 9% for those aged 45
years, which was similar to our ﬁnding [29]. Although different
elicitation methods and targeted populations were used in the
studies, this inconsistency still warrants future investigations.
The median of WTP/QALYQWB-SA value or WTP/QALYEQ-5D
value for the epilepsy group was nearly 2 times the gross
domestic product per capita in China (International Monetary
Fund, 2012, US $5417 for China), but fell within the range of
WHO’s recommendation (1–3 times the gross domestic product
per capita) [30]. On comparing with the result from a previous
WTP study, we see that patients with epilepsy afforded greater
amount of WTP and WTP/QALY values than did Chinese patients
with chronic prostatitis based on the same indirect utility
elicitation method (EQ-5D), and this might reﬂect the different
impacts on patients with these two chronic diseases.
In our study, WTP/QALYQWB-SA and WTP/QALYEQ-5D values
from the epilepsy group were a great deal higher than those from
the control group, suggesting that the WTP/QALY value is context
speciﬁc. In theory, perceptions of the WTP question for patients
with epilepsy and healthy subjects are essentially different. For
patients, the scenario provided is probably perceived as a cura-
tive treatment, whereas for healthy respondents, the scenario
offered is more like considering prevention because they are not
experiencing health problems at the moment of the study.
Because the WTP amount for prevention is remarkably less than
the quantity for treatment, an obvious difference in the WTP
value estimated from treatment and prevention situations waspreviously reported [21,31], According to a prospect theory, the
preference of an individual is related to a reference point [32]. In
our study, patients with epilepsy were in declined health states
compared with healthy subjects; thus, reference points for
epilepsy and healthy control cohorts were essentially distinctive.
This would offer another explanation for the huge gap in the WTP
amount between the two groups other than the inherent differ-
ence in the intangible cost for two distinct cohorts. Taken
together, these results also imply that one ceiling threshold
should not be applied to all the interventions when deciding
resource allocation.
Our present results showed that working status, seizure types,
monthly income, and self-rating health state might be predictors
of HRQOL of patients with epilepsy, which is in line with a
previous study [33], whereas epilepsy-speciﬁc parameters such as
age of epilepsy onset, duration of epilepsy, epileptic discharge
(electroencephalogram), seizure frequency, and antiepileptic
drugs did not statistically contribute to the variation in HRQOL.
A literature review, however, indicated that except for seizure
frequency, severity, and psychological factors, other disease
variables had affected HRQOL only in limited studies. Further-
more, the proportion of HRQOL variance explained by the MLR
model was low in our study, ranging from 14.9% to 42.1%
corresponding to different models and utility measures. This
might be due to the insensitivity of the generic preference-based
HRQOL instrument to capture characteristics inherent to a
speciﬁc disease. In addition, depression and anxiety have been
demonstrated to exert a high impact on HRQOL, but were not
independently assessed in our study (though there are items in
the EQ-5D and the QWB-SA to assess the psychological problems)
and thus not included in the MLR model [34,35].
Our study was subject to some limitations as well. First, a
direct utility elicitation method such as SG or TTO would be
superior to the indirect method as used in the present study. Both
SG and TTO, however, are hard to understand and respond for
participants; thus, indirect methods might serve as a substitute
to direct methods. This is supported by the higher convergent
validity between WTP/QALYQWB-SA and WTP/QALYEQ-5D in the
present study than in studies adopting SG and TTO. Second,
because epilepsy, generally, is not a life-threatening disease, as
reported by previous literature, a QALY gained by improving the
quality of life or extending a life is worth less than a QALY gained
by saving a life, so the WTP/QALY estimation derived from this
cohort might not be comprehensive enough to reﬂect the societal
perspective [36–39]. Last, epilepsy and control groups were
heterogeneous in terms of several sociodemographic character-
istics, which would introduce a confounding factor into the ﬁnal
result.Conclusions
Patients with epilepsy had substantially lower HRQOL than did
the healthy population. Seizure types, working status, monthly
income, and self-rating health state could be considered as
predictors of HRQOL of this cohort. In spite of controversies over
underlying theoretical and methodological issues, our study
demonstrated the feasibility and acceptability to quantify mon-
etary value per QALY with the WTP approach. Particularly, WTP/
month and the WTP/QALY value of patients with epilepsy were
considerably greater than those of the general population, which
also revealed increased intangible cost for the sufferers. Never-
theless, it is questionable to apply one WTP/QALY threshold to all
the situations. Finally, the methods to elicit QALY and WTP
should also be taken into consideration.
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